ZyVersa Therapeutics (ZVSA) vs. Its Peers Head-To-Head Analysis

Earnings & Valuation

This table compares ZyVersa Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	-$9.41 million	-0.04
ZyVersa Therapeutics Competitors	$959.51 million	-$45.50 million	11.85

ZyVersa Therapeutics’ peers have higher revenue, but lower earnings than ZyVersa Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ZyVersa Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
ZyVersa Therapeutics Competitors	-1,425.99%	-589.65%	-28.81%

Volatility & Risk

ZyVersa Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics’ peers have a beta of 0.97, indicating that their average share price is 3% less volatile than the S&P 500.

Summary

ZyVersa Therapeutics peers beat ZyVersa Therapeutics on 6 of the 9 factors compared.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.